EFP
CLRB icon

EnRich Financial Partners’s Cellectar Biosciences CLRB Stock Holding History

EnRich Financial Partners’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3
Closed -$30 – 82
2024
Q4 		$30 Hold
3
– – ﹤0.01% 219
2024
Q3 		$218 Hold
3
– – ﹤0.01% 223
2024
Q2 		$255 Hold
3
– – ﹤0.01% 241
2024
Q1 		$406 Buy
+3
New +$325 ﹤0.01% 196

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EnRich Financial Partners's CLRB Position: Q1 2025 in Review

EnRich Financial Partners sold out of Cellectar Biosciences (CLRB) in Q1 2025, closing a stake of 3 shares — an estimated $30 sold.

EnRich Financial Partners first reported a position in CLRB in Q1 2024 and held it in 4 quarters. The position peaked at $406 in Q1 2024. 32 funds tracked by Wall St. Rank hold CLRB as of Q1 2025.

  • EnRich Financial Partners reported no remaining Cellectar Biosciences position as of Q1 2025 after selling out during the quarter.
  • EnRich Financial Partners sold 3 Cellectar Biosciences shares in Q1 2025, an estimated $30.
  • EnRich Financial Partners first reported a position in Cellectar Biosciences in Q1 2024 and held it in 4 quarters.
  • EnRich Financial Partners's Cellectar Biosciences position peaked at $406 in Q1 2024.
  • 32 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2025.

Based on EnRich Financial Partners's 13F filing for Q1 2025, filed 25 Apr 2025.